Hemab Therapeutics Holdings, Inc.NASDAQ: COAG

Hemab Therapeutics to Participate in Upcoming Investor Conferences

· Issued by Hemab Therapeutics Holdings, Inc. via GlobeNewswire

Summary by 6ix AI

Hemab Therapeutics, a clinical-stage biotechnology company developing treatments for blood clotting disorders, said members of its management team will take part in two investor conferences and host investor meetings.

Key details

  • 2026 Jefferies Global Healthcare Conference in London, United Kingdom: fireside chat on Tuesday, November 17, 2026, at 5:00 PM GMT.
  • 9th Annual Evercore Healthcare Conference in Coral Gables, FL: fireside chat on Tuesday, December 1, 2026, at 3:00 PM ET.
  • A live webcast will be available for replay in the Events & Presentations part of the Investors section of Hemab Therapeutics' website.

6ix AI wrote this summary from the release below and checked it against the release.

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will participate in the following upcoming investor conferences and host investor meetings.

2026 Jefferies Global Healthcare Conference
Fireside Chat: Tuesday, November 17, 2026, at 5:00 PM GMT
Location: London, United Kingdom

9th Annual Evercore Healthcare Conference
Fireside Chat: Tuesday, December 1, 2026, at 3:00 PM ET
Location: Coral Gables, FL

A live webcast of the presentation and fireside chat will be available for replay under “Events & Presentations” section in the Investors section of Hemab Therapeutics’ website at hemab.com.

About Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.

Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Media:
Deerfield
Peg Rusconi
[email protected]

Investors:
Hemab Therapeutics
Mads Behrndt
[email protected]

View original source (GlobeNewswire)Hemab Therapeutics Holdings, Inc. on 6ix

Story so far

Earlier from Hemab Therapeutics

All Hemab Therapeutics news releases